-
Thrombin B-Chain Fragment: Identity and Research Use
2026-09-23
Thrombin is a trypsin-like serine protease with central roles in fibrin formation and platelet signaling. A1057 is a sequence-defined 17-residue thrombin B-chain fragment, so it should not be treated as intact, catalytically active thrombin.
-
MALAT1–miR-125b–STAT3 Axis in Sepsis PCT
2026-09-23
The reference study identifies a MALAT1–miR-125b–STAT3 regulatory circuit that increases procalcitonin expression in sepsis-related inflammatory models. Its combination of clinical samples, U937-cell experiments, fluorescence in situ hybridization, RNA interaction assays, and rescue experiments provides a mechanistic framework for interpreting PCT regulation, while leaving clinical validation and causal translation as important next steps.
-
Aβ42: From Ion Channels to AD Translation
2026-09-22
A mechanistic and translational guide to using Amyloid β-Peptide (1-42) in Alzheimer’s disease research, connecting aggregation state, neuronal ion channel modulation, neurotoxicity assays, and evidence from olive biophenol studies.
-
Ceruletide Workflows for Pancreatic Research
2026-09-22
Ceruletide, also called Caerulein in related literature, connects receptor stimulation with measurable pancreatic secretion, fibrosis, and gastrointestinal motility phenotypes. This workflow guide translates a recent ORM2–ZG16 fibrosis study into practical assay design, formulation controls, and troubleshooting decisions.
-
DREADDs and the Evolution of CNO-Activated GPCRs
2026-09-21
Armbruster and colleagues used directed molecular evolution to create muscarinic GPCRs activated by Clozapine N-oxide rather than acetylcholine. The study established DREADDs as experimentally validated receptors for separating receptor-specific and G-protein-coupled signaling in engineered cells and neurons.
-
A 83-01: ALK-5 Inhibitor for Organoids
2026-09-21
A 83-01 provides reversible control of TGF-β/Smad signaling for organoid, EMT, and growth-response experiments. This guide connects its defined pharmacology with patient-derived breast organoid workflows, emphasizing dose design, assay controls, and troubleshooting.
-
Intermedin, NAMPT/PARP1, and Vascular Senescence
2026-09-20
The 2025 reference study identifies intermedin as a protective regulator of angiotensin II–associated vascular smooth muscle cell senescence in mice. Its central mechanistic finding is that intermedin increases NAD+ through NAMPT and supports PARP1-associated DNA damage responses, offering a framework for understanding vascular aging without equating NAMPT activation with the inhibitory strategies used in oncology.
-
Protoporphyrin IX for Ferroptosis Workflows
2026-09-19
Protoporphyrin IX connects heme-pathway biology with light-triggered oxidative assays and exploratory ferroptosis research. This practical guide explains fresh-use handling, dark-versus-light controls, HCC assay design, and troubleshooting for insoluble photodynamic compounds.
-
Piroxicam and Deracoxib in Canine Mammary Cancer
2026-09-18
The 2012 reference study examined how piroxicam and deracoxib, alone and in combination, affect the canine mammary carcinoma cell line CMT-U27. Its main contribution was linking stronger combination-associated loss of viability with apoptosis and G0/G1 cell-cycle accumulation, while also clarifying that the evidence remains an in vitro pharmacology result rather than a validated clinical treatment.
-
Faropenem Transport by Renal Npt1
2026-09-18
The 2000 reference study used mouse Npt1 expressed in Xenopus oocytes to show that faropenem is transported across the renal epithelial luminal membrane through a sodium-independent, chloride-sensitive pathway. Its uptake, efflux, and competition experiments provide molecular evidence that Npt1 can contribute to active renal secretion of this penem antibiotic while also defining important limits for translating oocyte transport data to human pharmacokinetics.
-
Phosphotungstic Acid Negative Stain Solution for EM
2026-09-17
Turn fragile viruses, glycoprotein complexes, bacteria, and other macromolecules into high-contrast electron microscopy targets with a ready-to-use 2% negative stain. This workflow connects practical particle-quality control with emerging coronavirus glycan research while clearly separating structural imaging from antiviral proof.
-
AO/PI Double Staining Kit: Practical Protocol
2026-09-17
The AO/PI Double Staining Kit provides a rapid cell viability assay that separates viable, apoptotic-like, and membrane-compromised cells using Acridine Orange and Propidium Iodide fluorescence. It is suited to live-cell screening and routine fluorescence microscopy, but it should not be used alone to establish a definitive apoptotic mechanism or replace orthogonal validation.
-
Cy5 NHS ester(Et): Practical Labeling Guide
2026-09-16
Cy5 NHS ester(Et) is an amine-reactive fluorescent reagent for covalently labeling proteins, peptides, and other biomolecules for immunofluorescence, flow cytometry, and fluorescence microscopy. It is suited to freshly prepared aqueous or DMSO workflows, but not to ethanol-based protocols or long-term storage of working solutions.
-
Hypoxia and Immunometabolism in Tumors
2026-09-16
This 2025 review explains how oxygen deprivation and nutrient competition jointly reprogram tumor and immune-cell metabolism within the tumor microenvironment. Its central contribution is a systems-level framework linking HIF signaling, glucose dependence, immune dysfunction, and therapeutic opportunities while highlighting the limits of translating metabolic findings into clinical interventions.
-
ATRA Reverses Cisplatin-Linked PARP Resistance in EOC
2026-09-15
The reference study shows that cisplatin exposure can create a PARP inhibitor-resistant state in epithelial ovarian cancer through coordinated changes in NAD+ metabolism, aldehyde dehydrogenase activity, and DNA-damage signaling. It further identifies all-trans retinoic acid as a clinically relevant strategy for reducing this state and improving the activity of niraparib maintenance therapy in preclinical models.